Uncategorized

BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations

Published

on

BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version